Tag: Erdheim-Chester Disease

The U.S. Nourishment and Drug Administration today expanded the endorsement of Zelboraf (vemurafenib) to incorporate the treatment of certain grown-up patients with Erdheim-Chester Disease (ECD), an uncommon malignancy of the blood. Zelboraf is shown to treat patients whose disease cells have a particular hereditary change known as BRAF V600. This […]